Key Takeaways

  • EyePoint will reduce its workforce by approximately 53%, targeting $30 million in annualized savings

  • Duravyu missed the primary endpoint in both phase 3 wet AMD trials, prompting early termination of the studies

  • The company will prioritize its phase 3 DME program, with results expected in Q4 2027

EyePoint announced plans to reduce its workforce by approximately 53% and end its phase 3 wet age-related macular degeneration (AMD) trials early after its investigational therapy Duravyu (vorolanib intravitreal insert) failed to meet the primary endpoint in a second pivotal phase 3 study.

The restructuring, announced on Monday, is expected to generate approximately $30 million in annualized savings as the company shifts resources toward its late-stage Duravyu program in diabetic macular edema (DME).

The decision follows topline results from the phase 3 LUCIA trial, in which Duravyu failed to demonstrate statistical noninferiority to aflibercept in mean change in best-corrected visual acuity (BCVA), despite improvements in vision. The earlier phase 3 LUGANO trial also failed to meet its primary endpoint.

LUCIA enrolled 475 patients and LUGANO enrolled 432. Both evaluated Duravyu 2.7 mg administered every 24 weeks against aflibercept 2 mg every 8 weeks.

Despite missing their primary endpoints, both studies demonstrated reductions in treatment burden, favorable safety profiles with redosing, and sustained anatomic control through Week 56. More than 50% of Duravyu-treated patients remained free of supplemental injections through Week 56 in both trials. LUGANO demonstrated a 42% reduction in treatment burden compared with aflibercept (nominal P<.0001).

EyePoint plans to conduct additional analyses of the phase 3 datasets but will discontinue the trials before completing their second year.

The workforce reduction is expected to occur primarily during the fourth quarter of 2026 and be completed during the first half of 2027. EyePoint anticipates approximately $9 million in employee separation-related charges. The company reported approximately $118 million in cash, cash equivalents, and short-term investments as of September 30, 2026.

"Decisions involving a reduction in our workforce are exceptionally difficult, and we extend our deepest gratitude to our departing colleagues for their dedication and meaningful contributions," said Jay S. Duker, MD, president and CEO of EyePoint.

The company will now prioritize its phase 3 COMO and CAPRI trials evaluating Duravyu in DME. The studies enrolled a combined 551 patients and compare Duravyu 2.7 mg every 6 months with aflibercept every 8 weeks.

The DME program is supported by phase 2 VERONA findings, in which Duravyu met its primary endpoint of extending time to first supplemental injection. At Week 24, the 2.7-mg dose achieved a 7.1-letter BCVA gain, a 76-µm reduction in central subfield thickness, and a 73% supplement-free rate compared with 50% for aflibercept.

Topline results from COMO and CAPRI are expected in the fourth quarter of 2027.